Details

Autor(en) / Beteiligte

• Zhu, Ji
• Xu, Ye
• Gu, Weilie
• Peng, Junjie
• Cai, Gang
• Cai, Guoxiang
• Sun, Wenjie
• Shen, Weiqi
• Cai, Sanjun
• Zhang, Zhen

Titel

Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients

Ist Teil von

• Radiation oncology (London, England), 2010-12, Vol.5 (1), p.118-118, Article 118

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2010

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Adjuvant therapy for T3N0 rectal cancer was controversial with respect to both radiation and the use of a combined regimen of chemotherapy. We evaluated both clinical features and biomarkers and sought to determine risk factors for those patients retrospectively. A total of 122 patients with T3N0 rectal cancer were analyzed in this study from January 2000 to December 2005. Clinicopathologic and biomarkers were used to predict local recurrence (LR), disease-free survival (DFS), and overall survival (OS). The median follow-up interval was 45.4 months. Five-year LR, DFS, and OS rates were 10.4%, 68.3%, and 88.7%. Having a lower tumor location and showing low P21 and high CD44v6 expression were identified as risk factors for LR: patients with two or three of these risk factors had a higher 5-year LR rate (19.3%) than did patients with none or one of these risk factors (6.8%) (p = 0.05). A poorer DFS was related to low P21 nor high CD44v6 expression but not to tumor location: the 5-year DFS rates were 79.3% for those with neither, 65.9% for those with either one or the other, and 16.9% for those with both (p = 0.00). The prognostic model including tumor location, P21 and CD44v6 expressions could help to distinguish these patients with high risk T3N0 patients and determine whether adjuvant therapy was beneficial.